Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBER Counterfeit Procedures Stress Need For Improved Communication

Executive Summary

The Center for Biologics Evaluation & Research's standard procedures for responding to a counterfeit product event emphasizes the need for more efficient communication between FDA and outside parties

You may also be interested in...

FDA Anticounterfeit Carrot & Stick: Radio Frequency I.D., No Paper Pedigree

FDA's anticounterfeiting strategy advocates radio frequency identification in lieu of paper pedigrees to secure the drug supply chain

J&J Procrit Counterfeits Return: Contaminated Product Found In Florida

Johnson & Johnson's Ortho Biotech division appears to have a recurring problem with counterfeiting of Procrit in Florida

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts